医药魔方 / 最新资讯 / 正文

从跨国药企挖个CEO,要花多少钱?

医药魔方 医药魔方 来源:医药魔方
2019-01-09
CEO
原文

假设您是一家刚刚或即将商业化的中小型生物制药企业的董事会成员,肯定希望将来有位能够挑起商业化大梁,实现某些重大目标的首席执行官(CEO)。


谁的上任会让董事会自豪,让你也免于灾难?谁将激发股价的持续增长?传统的做法是去找一位在大型制药公司的执行委员会工作过的人。但这需要多少钱?本文挑选了4个例子,用以佐证挖掘这类CEO需要付出的代价和可能产生的回报。


这四位分别是Liz Barrett(曾担任辉瑞全球肿瘤学总裁,2018年1月加入诺华,现任Urogen公司CEO);Mark Mallon(原阿斯利康战略执行副总裁,现任Ironwood商业运营官);Jackie Fouse(之前担任过Celgene首席运营官,Roivant副主席,现任Agios公司CEO); Daniel O’Day(原罗氏制药CEO,即将担任吉利德CEO)。


Liz Barrett,56岁,首席执行官

公司: Urogen公司市值: 8.29亿美元原职位:诺华肿瘤科主管薪资:70万美元合同奖金:30万美元2019年奖金:100%薪资封顶,50%保底持有股票:317,065股普通股(以1月4日收盘价51.46美元计算,价值1630万美元)


期权:277,432股普通股,行权价格47.57美元/股


全部期权到手(Vested)时间:大于3年


编辑点评:UroGen创立于2004年,总部位于以色列Ra'anana,是一家临床阶段的生物制药公司,专注于开发泌尿科病理学疗法。如果从股票潜力的角度,不难发现招募Barrett的费用很高,但是没有人质疑Urogen为此付出的代价,因为Urogen近期有望获批首款癌症治疗药物。凭借突破性疗法认定和Ⅲ期数据,Barrett认为Urogen股票期权将在3年内表现良好。如果有买断,她可能不必等待。Urogen执行主席Arie Belldegrun曾将Kite出售给Gilead赚了不少钱,他也希望执行团队凭借自己的期权成为百万富翁。



Mark Mallon,56岁,首席执行官


公司:Ironwood公司市值: 18亿美元


原职位:阿斯利康战略薪酬副总裁


薪资:75万美元


合同奖金: 88万美元(带回拨条款)


股票:总价值350万美元的期权(一旦他正式成为CEO)


受限股票单位(RSU ):总价值350万美元(当他正式成为CEO时)


全部期权到手(Vested)时间:超过4年编辑点评:Peter Hecht创立了Ironwood,并决定在相当大的压力下将其分拆,从阿斯利康执行委员会挖来的Mark Mallon将负责分拆出的研发业务的运营。严格地讲, Mallon目前还相当于是公司高级顾问的角色。不过一旦他正式成为CEO,股票必将大幅增值。



Jackie Fouse,57岁,首席执行官


公司:Agios公司市值: 28亿美元原职位: Roivant副主席,Celgene的首席运营官薪资:72.5万美元合同奖金:8-K文件未提及


年度奖金: 65%的薪水


股票:1400万美元


编辑点评:Agios是成功完成第一轮药物开发工作的生物技术公司之一。执行主席David Schenkein是生物技术领域的顶级代表,Agios已经与Celgene密切合作。



Daniel O'Day,54岁,首席执行官


公司:Gilead原职位:罗氏制药首席执行官公司市值:880亿美元薪资:160万美元,预付现金567万美元奖金:150%薪资


股票:价值850万美元,期权300万美元


RSU:300万美元+基于绩效的600万美元


额外薪水:75万美元/年补贴,为期5年 


全部期权到手(Vested)时间:超过4年


编辑点评:Daniel O'Day加盟吉利德后,年度薪酬方案可能超过3000万美元。高薪酬的背后同样是董事会对他的高期望,期望他能带领吉利德保持艾滋病业务大规模增长,让CAR-T药物的业绩越来越好,并在NASH领域领先同行。


来源:Endpoints News. How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples。

作者:John Carroll

机器翻译

Suppose you are a member of the board of directors of a small or medium-sized biopharmaceutical company that has just been or is about to be commercialized, and you will certainly hope that there will be a CEO (CEO) who can provoke commercialization and achieve certain major goals in the future.

Who will make the board proud and save you from disaster?Who will spur continued stock price growth?The traditional approach is to find someone who has worked on the executive boards of large pharmaceutical companies.But how much does it cost?Four examples are selected to illustrate the costs and possible rewards of mining such CEOs.

These four are Liz Barrett (formerly President of Pfizer Global Oncology, joined Novartis in January 2018, and currently CEO of Urogen); Mark Mallon (formerly Executive Vice President of AstraZeneca Strategy, currently Business Operations Officer of Ironwood); Jackie Fouse (formerly Chief Operating Officer of Celgene, Vice President of Roivant, and currently CEO of Agios); Daniel O'Day (formerly CEO of Roche Pharmaceuticals, and soon to be CEO of Gilead).

Liz Barrett, 56, CEO

Company: Urogen Company Market Value: 8.2.9 billion U.S. dollars Original position: Novartis Oncology Head salary: 700,000 U.S. dollars Contract bonus: 300,000 U.S. dollars 2019 bonus: 100% salary cap, 50% guarantee holding stock: 317,065 common shares (closing price on January 4 51.$46, valued at $16.3 million)

Option: 277, 432 common stock, exercise price 47.$57/share

All options to hand (Vested) Time: Greater than 3 years

Editorial Comments: UroGen was founded in 2004 and is headquartered in Ra'anana, Israel. It is a clinical stage biopharmaceutical company focused on the development of urological pathology therapies.From the perspective of stock potential, it is not difficult to find that the cost of recruiting Barrett is high, but no one questions the price that Urogen has paid for this because Urogen is expected to be approved for the first cancer treatment drug in the near future.With breakthrough therapies and phase III data, Barrett believes that Urogen stock options will perform well within three years.If there is a buyout, she may not have to wait.Urogen executive chairman Arie Belldegrun made a lot of money selling Kite to Gilead, and he wants the executive team to become millionaires with his options.

Mark Mallon, 56, CEO

Company: Ironwood Company Market Value: $1.8 billion

Original position: Vice President, Strategic Pay, AstraZeneca

Pay: $750,000

Contract bonus:$880,000 (back dial clause)

Stock: Total $3.5 million option (once he officially became CEO)

Restricted Stock Unit (RSU): Total $3.5 million (when he officially became CEO)

Total Option to Hand (Vested) Time: Over 4 years Editor's Comment: Peter Hecht founded Ironwood and decided to split it under considerable pressure. Mark Mallon, who was dug up from AstraZeneca's executive committee, will be responsible for the operation of the split R & D business.Strictly speaking, Mallon is still equivalent to being a senior adviser to the company.But once he is officially ceo, the stock will add a lot.

Jackie Fouse, 57, CEO

Company: Agios Company Market Value: $2.8 billion Original position: Vice President Roivant, Chief Operating Officer of Celgene Pay: 72.$50,000 Contract bonus: The 8-K document does not mention

Annual bonus: 65% of salary

Stock: $14 million

Editorial Comment: Agios is one of the biotech companies that successfully completed the first round of drug development work.Executive Chairman David Schenkein is a top representative in biotechnology and Agios has worked closely with Celgene.

Daniel O 'Day, 54, CEO

Company: Gilead Original position: Roche Chief Executive Officer Company Market Value: $8.8 billion Pay: $1.6 million, prepaid cash $5.67 million bonus: 150% Pay

Stock: $8.5 million, Option $3 million

RSU: $3 million + Performance-based $6 million

Additional salary: $0.75 million/year subsidy for 5 years

All options to hand (Vested) Time: more than 4 years

Editorial Comments: After Daniel O 'Day joined Gilead, the annual compensation plan may exceed 30 million US dollars.Behind the high salary is also the high expectations of the board of directors, hoping that he can lead Gilead to maintain large-scale growth of the AIDS business, so that the performance of CAR-T drugs is getting better and better, and lead colleagues in the NASH field.

Source: Endpoints News.How much does it cost to hire a top Big Pharma Exec to run a biotech?Here are 4 (very) fresh samples.

Author: John Carroll

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号